Dazucorilant 150 mg ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05407324 (ClinicalTrials.gov) | November 15, 2022 | 2/6/2022 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS) | Amyotrophic Lateral Sclerosis | Drug: Dazucorilant 300 mg;Drug: Dazucorilant 150 mg;Other: Placebo | Corcept Therapeutics | NULL | Recruiting | 18 Years | N/A | All | 198 | Phase 2 | Belgium;France;Netherlands;Poland |